Workflow
创新医疗
icon
Search documents
清华团队研发脑机接口新方案,侧脑室灯笼电极实现稳定记录:机械设备
Huafu Securities· 2026-02-28 09:26
行 业 研 华福证券 这款侧脑室灯笼电极在功能上表现亮眼,在记忆引导决策的动物 实验中,其构建的分类模型预测准确率最高近 98%,显著优于传统皮 层电极,还能捕获更多与记忆、决策相关的神经区域信息。该研究从 植入位置和电极结构双维度创新,为提升侵入式脑机接口长期稳定性 提供了新技术方向,也为获取深部认知相关信息开辟了新路径,其提 出的"脑室通路"概念为脑机接口设计提供新参考,未来该技术还需 在器件优化、人体适配等方面进一步验证。 "十五五"重点赛道,脑机接口市场规模有望快速增长 根据 precedence research,2024 年全球脑机接口市场规模约为 26.2 亿美元,预计 2025 年将达到 29.4 亿美元,到 2034 年有望增长至 124 亿美元,十年间复合年增长率为 17.35%;据工信微报,2024 年中国脑 机接口市场规模为 32.0 亿元,预计到 2028 年将达 61.4 亿元。《中共 中央关于制定国民经济和社会发展第十五个五年规划的建议》提出前 瞻布局未来产业,推动脑机接口等成为新的经济增长点。这些产业蓄 势发力,未来 10 年将再造一个中国高技术产业。 华福证券 建议关注 机械 ...
未知机构:WSJ预计中将在定于3月公布的下一个五年计划中重点提及BCI侵入式脑机技术-20260228
未知机构· 2026-02-28 02:40
事件:2月27日,华尔街日报显示,马斯克、阿尔特曼和中国角逐脑机接口领域,瞄准3,200亿美元潜在市场,预 计中国将在定于3月公布的下一个五年计划中重点提及BCI技术。 事件:2月27日,华尔街日报显示,马斯克、阿尔特曼和中国角逐脑机接口领域,瞄准3,200亿美元潜在市场,预 计中国将在定于3月公布的下一个五年计划中重点提及BCI技术。 【南京熊猫电子】聚焦非侵入式多模态交互,覆盖医疗、工业、军工,脑控外骨骼临床试用,2026 年冲刺三类 证。 【创新医疗】参股博灵脑机,推进植入式 BCI 外骨骼临床试验,2026 上半年申报注册,剑指国内首款获批。 【南京熊猫电子】聚焦非侵入式多模态交互,覆盖医疗、工业、军工,脑控外骨骼临床试用,2026 年冲刺三类 证。 WSJ预计中将在定于3月公布的下一个五年计划中重点提及BCI(侵入式脑机)技术。 WSJ预计中将在定于3月公布的下一个五年计划中重点提及BCI(侵入式脑机)技术。 ...
医疗服务板块2月27日涨0.32%,创新医疗领涨,主力资金净流入2.39亿元
Sou Hu Cai Jing· 2026-02-27 08:47
证券之星消息,2月27日医疗服务板块较上一交易日上涨0.32%,创新医疗领涨。当日上证指数报收于 4162.88,上涨0.39%。深证成指报收于14495.09,下跌0.06%。医疗服务板块个股涨跌见下表: 从资金流向上来看,当日医疗服务板块主力资金净流入2.39亿元,游资资金净流出3132.0万元,散户资 金净流出2.08亿元。医疗服务板块个股资金流向见下表: 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成 投资建议。 ...
药监局2025年共收到创新医疗器械特别审批申请457项,医疗创新ETF(516820)盘中飘红
Xin Lang Cai Jing· 2026-02-27 05:30
消息面上,国家药监局发布2025年度创新医疗器械等产品注册审批情况,2025年,国家药监局按照《创 新医疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作,共收到创新医疗 器械特别审批申请457项,其中104项获准进入创新医疗器械特别审查程序;收到优先申请38项,其中26 项获准优先审批。 华福证券指出,考虑到医药已调整半年,很充分,继续坚定医药科技主线,26年全年策略如下:1)创 新药:主要三个方向:1、收入和业绩兑现;2、超预期BD兑现的标的;3、前沿技术平台如分子胶、小 核酸、通用/体内CART、基因治疗等弹性主题;2)医疗器械:设备看补库和招投标,如手术机器人和 内镜等,耗材看集采受益的创新耗材如神经介入、外周介入和电生理等方向;3)寻找变化标的:考虑 到中央经济工作会议明确提到26年坚持内需主导,建设强大国内市场,期待内需消费崛起,医药内需相 关公司或将迎来拐点。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数,中证医药及医疗器械创新指数从医药卫生行业的 上市公司中,选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本, 以反映兼具盈利性与成长性的医药 ...
万和财富早班车-20260226
Vanho Securities· 2026-02-26 02:01
Domestic Financial Market - The Shanghai Composite Index closed at 4147.23, with an increase of 0.72% [4] - The Shenzhen Component Index closed at 14475.87, rising by 1.29% [4] - The ChiNext Index closed at 3354.82, up by 1.41% [4] Macro News Summary - On February 25, the central bank conducted a 600 billion MLF operation for a one-year term to maintain liquidity in the banking system [6] - The National Energy Administration is working to enhance oil and gas infrastructure connectivity while considering the needs for green hydrogen and ammonia transportation [6] - The Financial Secretary of Hong Kong announced that the Hong Kong Stock Exchange will consult the market on the implementation plan for the "T+1" settlement cycle in the first half of the year [6] Industry Dynamics - The domestic fertilizer market is experiencing a general price increase, with key stocks such as Liuguo Chemical and Chuanfa Longmang showing potential [7] - The State Council is focusing on the silver economy and the development of elderly care services, indicating significant potential in this sector, with related stocks including Innovation Medical and Kaidi Co. [7] - Google announced plans to build a new data center, advancing green electricity and energy storage initiatives, with related stocks like Sungrow Power Supply and Guodian NARI [7] Company Focus - Shunwang Technology is steadily advancing the construction of cloud-edge computing rooms, integrating more high-performance graphics card computing power to meet application demands [8] - Kaige Precision Machinery has delivered 800G and 1.6T optical module automation assembly product lines to overseas clients [8] - Yangdian Technology's dry-type transformer products are now being applied in data center infrastructure [8] - Ningbo Huaxiang is responsible for the OEM business of the Zhiyuan Expedition series, with the 6-degree-of-freedom dexterous hand product currently in the final stages of development and testing [8] Market Review and Outlook - The market showed a noticeable recovery post-holiday, with increased individual stock activity and the Shanghai Composite Index closing positively, indicating a solid foundation for future advances [9] - The market experienced a broad increase, with over 3700 stocks rising, and a significant number of stocks hitting the daily limit for two consecutive days, reflecting a general bullish trend [9] - Caution is advised as the index shows signs of divergence at higher time frames, and attention should be paid to the speed and volume of index rebounds [10]
畅通科技—产业—金融高水平循环
Guo Ji Jin Rong Bao· 2026-02-24 11:38
Core Insights - Shanghai's International Science and Technology Innovation Center is transitioning from "innovation sourcing" to "results transformation," focusing on integrating innovation chains, industry chains, talent chains, and capital chains to accelerate the conversion of innovative achievements into productive forces [1][4][7] Group 1: Achievements and Goals - By 2025, the three leading industries—integrated circuits, biomedicine, and artificial intelligence—are expected to exceed a total scale of 2 trillion yuan, with high-tech industry output surpassing 900 billion yuan, accounting for 22.2% of industrial output [1] - The 2025 Shanghai Science and Technology Progress Report indicates that R&D expenditure intensity is projected to reach around 4.5%, with basic research investment intensity increasing to approximately 12% [2] - Shanghai's integrated circuit industry is expected to account for over 25% of the national market, with more than 1,000 enterprises and 40% of national talent concentrated in the region [2] Group 2: Financial and Talent Development - A future industry fund of 15 billion yuan has leveraged six times the amount of social capital, while the "Big Zero Bay" fund matrix has a total scale of 27.3 billion yuan [3] - By 2025, Shanghai is expected to have 187 academicians and attract over 160 foreign young scientists from 42 countries through the "Shanghai Partner Research Program" [3] Group 3: Policy and Structural Changes - The focus during the "14th Five-Year Plan" period is shifting from quantity accumulation to "empowering capital circulation," enhancing market resource allocation efficiency and risk management functions [4][7] - The government aims to support small and medium-sized technology enterprises through inclusive financing and direct investment, enhancing the operational capabilities of state-owned funds [4][7] - Breaking down institutional barriers is essential for creating a service-oriented innovation ecosystem, with an emphasis on forming innovation consortia led by leading enterprises [7]
2025年中国脑机接口行业细分产品市场分析 非侵入式脑机接口是市场上最为普遍的消费级设备【组图】
Qian Zhan Wang· 2026-02-24 06:11
本文核心数据:脑机接口领域细分市场情况;脑机接口领域侵入式脑机接口分析 1、中国脑机接口行业细分市场情况 脑机接口按照信号采集方式可以通常分为侵入式、半侵入式和非侵入式三大类别。目前侵入式脑机接口 的研究主要集中在开发新型材料以及更精细的电极以提高生物相容性,非侵入式产品研究主要集中在改 进材料以提升电极导电率、改进结构以促进电极与皮肤充分接触。较多公司侧重开发非侵入式产品,涉 及教育和泛娱乐、健康和睡眠辅助等。在侵入式领域内深耕的国内公司为数不多,少量公司正在开发无 创或微创的产品与解决方案,以用来进行脑科学研究、精神与心理疾病筛查,各类神经系统疾病监护、 诊疗与康复。 转自:前瞻产业研究院 以下数据及分析来自于前瞻产业研究院脑机接口研究小组发布的《全球及中国脑机接口(BCI)行业发 展前景展望与投资机遇分析报告》。 行业主要上市公司:翔宇医疗(688626)、岩山科技(002195)、科大讯飞(002230)、伟思医疗(688580)、爱 朋医疗(300753)、三博脑科(301293)、创新医疗(002173)等 2、侵入式脑机接口分辨率高 侵入式脑机接口指通过神经外科手术将电极等信号记录装置植入脑内特 ...
创新医疗(002173)2月13日主力资金净买入8561.17万元
Sou Hu Cai Jing· 2026-02-24 01:28
证券之星消息,截至2026年2月13日收盘,创新医疗(002173)报收于29.46元,上涨1.62%,换手率 10.8%,成交量44.95万手,成交额13.19亿元。 2月13日的资金流向数据方面,主力资金净流入8561.17万元,占总成交额6.49%,游资资金净流入 2584.81万元,占总成交额1.96%,散户资金净流出1.11亿元,占总成交额8.45%。 近5日资金流向一览见下表: 注:主力资金为特大单成交,游资为大单成交,散户为中小单成交 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成 投资建议。 创新医疗融资融券信息显示,融资方面,当日融资买入1.11亿元,融资偿还1.23亿元,融资净偿还 1214.39万元。融券方面,融券卖出0.0股,融券偿还0.0股,融券余量1.37万股,融券余额40.36万元。融 资融券余额5.61亿元。 创新医疗2025年三季报显示,前三季度公司主营收入5.97亿元,同比下降2.11%;归母净利润472.44万 元,同比上升116.97%;扣非净利润-2946.98万元,同比上升6.05%;其中2025年第 ...
微创心通-B涨超6% 植入式心律转复除颤器进入创新医疗器械特别审查程序
Zhi Tong Cai Jing· 2026-02-16 03:35
微创心通-B(02160)涨超6%,截至发稿,涨6.33%,报0.84港元,成交额859.92万港元。 消息面上,2月13日晚,微创心通发布公告称,近日,国家药品监督管理局"NMPA"医疗器械技术审评 中心发布《创新医疗(002173)器械特别审查申请审查结果公示(2026年第3号)》,拟同意集团旗下新 一代植入式心律转复除颤器(ICD)TILEN/EYLEN(泰然╱怡然)进入创新医疗器械特别审查程序(NMPA绿 色通道)。据此,TILEN/EYLEN(泰然╱怡然)有望成为国内首款获批的具备自主知识产权的磁共振条件 安全ICD。 ...
港股异动 | 微创心通-B(02160)涨超6% 植入式心律转复除颤器进入创新医疗器械特别审查程序
智通财经网· 2026-02-16 03:33
消息面上,2月13日晚,微创心通发布公告称,近日,国家药品监督管理局"NMPA"医疗器械技术审评 中心发布《创新医疗器械特别审查申请审查结果公示(2026年第3 号)》,拟同意集团旗下新一代植入式 心律转复除颤器(ICD)TILEN/EYLEN (泰然╱怡然)进入创新医疗器械特别审查程序(NMPA绿色通道)。 据此 ,TILEN/EYLEN(泰然╱怡然)有望成为国内首款获批的具备自主知识产权的磁共振条件安全 ICD。 微创心通-B(02160)涨超6%,截至发稿,涨6.33%,报0.84港元,成交额859.92万港元。 ...